Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-07-08FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited to market the generic product for the same ind…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder [Phase 3]
Phase 3 safety and tolerability trial of lumateperone (Caplyta) in pediatric patients with schizophrenia, bipolar disorder, or autism spectr…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
This clinical trial update reports a real-world assessment of brexpiprazole (Rexulti) for schizophrenia and depressive disorders, currently …
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans [Phase 1]
This Phase 1 clinical trial at Yale University aims to study the genetics of cannabis use disorder and individual cannabinoid response in hu…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia [NA]
This clinical trial investigates a cognitive remediation approach using rhythmic, vocal, and corporeal musical learning for schizophrenia an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia [Phase 2]
A Phase 2 study evaluating luvadaxistat for cognitive impairment in schizophrenia has been terminated. The trial was sponsored by Neurocrine…
-
FDA approval · 2025-07-01FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for HALOPERIDOL DECANOATE by Fresenius Kabi USA, LLC.
-
FDA approval · 2025-07-01FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Lurasidone Hydrochloride from Macleods Pharmaceuticals Limited, authorizing the generic product.…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? [Phase 4]
Phase 4 clinical trial investigated whether adding divalproex sodium ER to an atypical antipsychotic improves cognition and psychopathology …
-
FDA approval · 2025-06-24FDA Approved: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic Perphenazine and Amitriptyline Hydrochloride product by Mylan Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and [NA]
This terminated clinical trial in China investigated the occurrence and influencing factors of cognitive impairment in elderly patients with…
-
CLINICAL_TRIALS trial_result · 2025-06-22Clinical Trial Update: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating MMFS-202-302 for cognitive enhancement in schizophrenia and schizoaffective disorder has completed. Result…
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease
A clinical trial update shows DISC1 is being explored as a biomarker for cardiovascular disease, with the study currently active but not rec…
-
FDA approval · 2025-06-20FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for Haloperidol Decanoate from Fresenius Kabi USA, LLC, indicating regulatory authorization for …
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Investigation of the Effects of Virtual Reality Applications on Individuals Diagnosed With Schizophrenia [NA]
This entry reports a clinical trial evaluating the effects of virtual reality applications in individuals diagnosed with schizophrenia; the …
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: The Personal Recovery Based Psychoeducation For Schizophrenia [NA]
A completed clinical trial evaluating a personal recovery-based psychoeducation program for individuals with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This completed trial update reports on the risk of various mental health conditions among children and young adults with inflammatory bowel …
-
FDA approval · 2025-06-13FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for a generic Clozapine product from Mylan Pharmaceuticals (ANDA201824). This action expands acc…
-
FDA approval · 2025-06-13FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals Inc. to market a generic clozapine product (Clozapine) through an ANDA.
-
FDA approval · 2025-06-13FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
The FDA notes a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc., seeking a regulatory change to …
-
FDA approval · 2025-06-13FDA Approved: CLOZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approves a supplemental application for Clozapine submitted by Teva Pharmaceuticals USA, Inc., resulting in an approved supplemental…
-
FDA approval · 2025-06-13FDA Approved: CLOZAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Clozapine from Accord Healthcare Inc., approving a change to the approved product.
-
FDA approval · 2025-06-13FDA Approved: CLOZAPINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Clozapine submitted by Aurobindo Pharma Limited.
-
FDA approval · 2025-06-13FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
The FDA approved a supplemental application for Versacloz (clozapine) submitted by TruPharma LLC.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: The Effectiveness of Psychosocial Skills Training Applied to Individuals Diagnosed With Schizophrenia [NA]
The document reports on a completed clinical trial evaluating the effectiveness of psychosocial skills training for individuals diagnosed wi…